Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.

Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.

老虎证券2026/03/28 19:32

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This groundbreaking achievement highlights the synergistic effect of combination therapy, providing new clinical evidence for the treatment of related diseases. A comprehensive analysis of the research data will further support the prospects for the application of this therapy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.

You may also like

Crypto prices